Preparing for the upcoming 2022/23 influenza season: A modelling study of the susceptible population in Australia, France, Germany, Italy, Spain and the United Kingdom

We analysed the influenza epidemic that occurred in Australia during the 2022 winter using an age‐structured dynamic transmission model, which accounts for past epidemics to estimate the population susceptibility to an influenza infection. We applied the same model to five European countries. Our analysis suggests Europe might experience an early and moderately large influenza epidemic. Also, differences may arise between countries, with Germany and Spain experiencing larger epidemics, than France, Italy and the United Kingdom, especially in children.

[1]  E. Azziz-Baumgartner,et al.  Influenza Incidence and Vaccine Effectiveness During the Southern Hemisphere Influenza Season — Chile, 2022 , 2022, MMWR. Morbidity and mortality weekly report.

[2]  E. Lau,et al.  Prediction of upcoming global infection burden of influenza seasons after relaxation of public health and social measures during the COVID-19 pandemic: a modelling study , 2022, The Lancet Global Health.

[3]  J. Paget,et al.  Has influenza B/Yamagata become extinct and what implications might this have for quadrivalent influenza vaccines? , 2022, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[4]  C. Macintyre,et al.  Letter to the editor: Increase of influenza vaccination coverage rates during the COVID-19 pandemic and implications for the upcoming influenza season in northern hemisphere countries and Australia , 2021, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[5]  C. Macintyre,et al.  Modelling the influenza disease burden in people aged 50–64 and ≥65 years in Australia , 2021, Influenza and other respiratory viruses.

[6]  B. Cowling,et al.  Human seasonal influenza under COVID-19 and the potential consequences of influenza lineage elimination , 2021, Nature Communications.

[7]  L. Coudeville,et al.  Potential impact of introducing vaccines against COVID-19 under supply and uptake constraints in France: A modelling study , 2021, PloS one.

[8]  S. Majumdar,et al.  A global panel database of pandemic policies (Oxford COVID-19 Government Response Tracker) , 2021, Nature Human Behaviour.

[9]  A. Chit,et al.  Exploring uncertainty and risk in the accelerated response to a COVID-19 vaccine: Perspective from the pharmaceutical industry , 2020, Vaccine.

[10]  Seattle,et al.  Inferring high-resolution human mixing patterns for disease modeling , 2020, Nature communications.

[11]  L. Brammer,et al.  The epidemiological signature of influenza B virus and its B/Victoria and B/Yamagata lineages in the 21st century , 2019, PloS one.

[12]  Wladimir J Alonso,et al.  The spatiotemporal characteristics of influenza A and B in the WHO European Region: can one define influenza transmission zones in Europe? , 2017, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[13]  E. Clay,et al.  Public health and economic impact of seasonal influenza vaccination with quadrivalent influenza vaccines compared to trivalent influenza vaccines in Europe , 2016, Human vaccines & immunotherapeutics.

[14]  Pascal Crépey,et al.  Retrospective public health impact of a quadrivalent influenza vaccine in the United States , 2015, Influenza and other respiratory viruses.

[15]  R. Evans.  European Centre for Disease Prevention and Control. , 2014, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[16]  L. Kramer,et al.  Perspective of the Pharmaceutical Industry , 1990 .